So the practical comparison narrows to a few questions: does the dual mechanism suit your situation, which indication applies to you, and what will your plan cover for that use
Coverage for GLP-1 medications for weight loss is inconsistent and varies widely by plan
Subsequently, pharmacologic agonism of GLP-2 has gathered interest for the treatment of patients with conditions pertaining to the loss of intestinal anatomical and/or functional integrity to a degree requiring parenteral support, collectively referred to as intestinal failure
"They are making long-term promises based on short-term data," she says, pointing out that even that data "still doesn't necessarily actually support the claims that they're making." Dr
[65] [66] The Cochrane reviews [note 7] on the treatment of ADHD in children, adolescents, and adults with pharmaceutical amphetamines stated that short-term studies have demonstrated that these drugs decrease the severity of symptoms, but they have higher discontinuation rates than non-stimulant medications due to their adverse side effects
